Does the media favor ATRA or ORIC?

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Oric Pharmaceuticals. Atara Biotherapeutics' average media sentiment score of 1.07 beat Oric Pharmaceuticals' score of 0.48 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IRD or ATRA more profitable?

Atara Biotherapeutics has a net margin of -269.42% compared to Opus Genetics' net margin of -1,091.82%. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% N/A -150.13% Atara Biotherapeutics -269.42% N/A -73.01%

Does the media refer more to IRD or ATRA?

In the previous week, Opus Genetics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for Opus Genetics and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat Opus Genetics' score of 0.90 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AGEN or ATRA?

In the previous week, Agenus had 4 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Agenus and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat Agenus' score of 0.58 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATRA or ARCT?

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat Arcturus Therapeutics' score of 0.78 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CCCC or ATRA?

In the previous week, C4 Therapeutics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for C4 Therapeutics and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat C4 Therapeutics' score of 0.68 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Atara Biotherapeutics (ATRA) Competitors

$9.66 +0.35 (+3.76%)

As of 10:04 AM Eastern

Compare

ATRA vs. ORIC, IRD, AGEN, ARCT, and CCCC

Should you buy Atara Biotherapeutics stock or one of its competitors? Atara Biotherapeutics's main competitors and comparable companies include Oric Pharmaceuticals (ORIC), Opus Genetics (IRD), Agenus (AGEN), Arcturus Therapeutics (ARCT), and C4 Therapeutics (CCCC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Oric Pharmaceuticals. Atara Biotherapeutics' average media sentiment score of 1.07 beat Oric Pharmaceuticals' score of 0.48 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.77	$32.69M	-$1.18	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 2.04%. Oric Pharmaceuticals has a consensus price target of $20.67, suggesting a potential upside of 82.73%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Atara Biotherapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	N/A	-73.01%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Summary

Atara Biotherapeutics beats Oric Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, Opus Genetics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for Opus Genetics and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat Opus Genetics' score of 0.90 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Opus Genetics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	24.68	-$49.59M	-$1.35	N/A
Atara Biotherapeutics	$120.77M	0.77	$32.69M	-$1.18	N/A

Atara Biotherapeutics has a net margin of -269.42% compared to Opus Genetics' net margin of -1,091.82%.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Atara Biotherapeutics	-269.42%	N/A	-73.01%

Opus Genetics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Opus Genetics presently has a consensus target price of $12.29, indicating a potential upside of 189.76%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 2.04%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Atara Biotherapeutics beats Opus Genetics on 8 of the 14 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Agenus?

Agenus (NASDAQ:AGEN) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Agenus has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Agenus currently has a consensus price target of $24.50, indicating a potential upside of 252.52%. Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 2.04%. Given Agenus' higher possible upside, equities analysts plainly believe Agenus is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Agenus has a net margin of 69.33% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of 0.00% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Atara Biotherapeutics	-269.42%	N/A	-73.01%

61.5% of Agenus shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 6.5% of Agenus shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Agenus. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.75	$120K	$2.58	2.69
Atara Biotherapeutics	$120.77M	0.77	$32.69M	-$1.18	N/A

In the previous week, Agenus had 4 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Agenus and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat Agenus' score of 0.58 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Agenus beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Arcturus Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Atara Biotherapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market.

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat Arcturus Therapeutics' score of 0.78 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential upside of 2.04%. Arcturus Therapeutics has a consensus price target of $22.00, indicating a potential upside of 82.88%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Atara Biotherapeutics has a net margin of -269.42% compared to Arcturus Therapeutics' net margin of -317.62%. Atara Biotherapeutics' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	N/A	-73.01%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

Atara Biotherapeutics has higher revenue and earnings than Arcturus Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.77	$32.69M	-$1.18	N/A
Arcturus Therapeutics	$82.03M	4.17	-$65.78M	-$3.31	N/A

Summary

Arcturus Therapeutics beats Atara Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Atara Biotherapeutics has higher revenue and earnings than C4 Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	9.51	-$104.99M	-$1.00	N/A
Atara Biotherapeutics	$120.77M	0.77	$32.69M	-$1.18	N/A

In the previous week, C4 Therapeutics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for C4 Therapeutics and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.07 beat C4 Therapeutics' score of 0.68 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

C4 Therapeutics has a beta of 3.07, meaning that its stock price is 207% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

C4 Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 205.76%. Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 2.04%. Given C4 Therapeutics' higher possible upside, equities analysts clearly believe C4 Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Atara Biotherapeutics has a net margin of -269.42% compared to C4 Therapeutics' net margin of -289.44%. Atara Biotherapeutics' return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Atara Biotherapeutics	-269.42%	N/A	-73.01%

Summary

C4 Therapeutics beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$96.99M	$3.88B	$7.26B	$13.10B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-8.19	13.21	275.54	25.58
Price / Sales	0.80	1,131.68	557.67	80.26
Price / Cash	1.93	118.50	77.16	53.04
Price / Book	-1.81	17.16	10.81	6.02
Net Income	$32.69M	-$22.65M	$3.49B	$380.34M
7 Day Performance	3.09%	-4.64%	-3.00%	-3.19%
1 Month Performance	4.43%	-12.66%	-7.48%	-6.07%
1 Year Performance	-33.88%	8.08%	3.18%	-3.77%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	2.047 of 5 stars	$9.66 +3.8%	$9.50 -1.7%	-38.1%	$96.99M	$120.77M	N/A	10	Positive News
ORIC Oric Pharmaceuticals	2.9105 of 5 stars	$12.49 +2.4%	$20.67 +65.5%	-18.7%	$1.27B	N/A	N/A	111	Analyst Forecast
IRD Opus Genetics	2.8795 of 5 stars	$4.38 -4.4%	$11.92 +172.2%	+112.0%	$378.53M	$9.86M	N/A	28	Gap Up
AGEN Agenus	3.0927 of 5 stars	$8.73 +4.4%	$24.50 +180.6%	+71.6%	$377.55M	$114.20M	3.38	81
ARCT Arcturus Therapeutics	2.8871 of 5 stars	$14.66 +12.5%	$22.43 +53.0%	-38.0%	$370.35M	$82.03M	N/A	111	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, IRD, AGEN, ARCT, and CCCC

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Opus Genetics?

Summary

How does Atara Biotherapeutics compare to Agenus?

Summary

How does Atara Biotherapeutics compare to Arcturus Therapeutics?

Summary

How does Atara Biotherapeutics compare to C4 Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, IRD, AGEN, ARCT, and CCCC

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Do institutionals and insiders hold more shares of ATRA or ORIC?

Does the media favor ATRA or ORIC?

Which has stronger earnings and valuation, ATRA or ORIC?

Do analysts rate ATRA or ORIC?

Which has more risk and volatility, ATRA or ORIC?

Is ATRA or ORIC more profitable?

Summary

How does Atara Biotherapeutics compare to Opus Genetics?

Does the media refer more to IRD or ATRA?

Do insiders and institutionals hold more shares of IRD or ATRA?

Which has higher earnings and valuation, IRD or ATRA?

Is IRD or ATRA more profitable?

Which has more volatility & risk, IRD or ATRA?

Do analysts prefer IRD or ATRA?

Summary

How does Atara Biotherapeutics compare to Agenus?

Which has more volatility and risk, AGEN or ATRA?

Do analysts prefer AGEN or ATRA?

Is AGEN or ATRA more profitable?

Do insiders & institutionals hold more shares of AGEN or ATRA?

Which has preferable valuation and earnings, AGEN or ATRA?

Does the media prefer AGEN or ATRA?

Summary

How does Atara Biotherapeutics compare to Arcturus Therapeutics?

Which has more risk & volatility, ATRA or ARCT?

Does the media favor ATRA or ARCT?

Do institutionals and insiders believe in ATRA or ARCT?

Do analysts prefer ATRA or ARCT?

Is ATRA or ARCT more profitable?

Which has higher valuation & earnings, ATRA or ARCT?

Summary

How does Atara Biotherapeutics compare to C4 Therapeutics?

Which has better valuation and earnings, CCCC or ATRA?

Does the media refer more to CCCC or ATRA?

Do insiders & institutionals believe in CCCC or ATRA?

Which has more volatility and risk, CCCC or ATRA?

Do analysts prefer CCCC or ATRA?

Is CCCC or ATRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools